TY - JOUR
T1 - Nuclear Receptors as Therapeutic Targets in Liver Disease
T2 - Are We There Yet?
AU - Rudraiah, Swetha
AU - Zhang, Xi
AU - Wang, Li
N1 - Funding Information:
L.W. is supported by NIH R01DK080440, R01DK104656, R01ES025909, VA Merit Award 1I01BX002634, R21AA022482, and R21CA191507.
Publisher Copyright:
Copyright © 2016 by Annual Reviews. All rights reserved.
PY - 2016/1/6
Y1 - 2016/1/6
N2 - Nuclear receptors (NR) are ligand-modulated transcription factors that play diverse roles in cell differentiation, development, proliferation, and metabolism and are associated with numerous liver pathologies such as cancer, steatosis, inflammation, fibrosis, cholestasis, and xenobiotic/drug-induced liver injury. The network of target proteins associated with NRs is extremely complex, comprising coregulators, small noncoding microRNAs, and long noncoding RNAs. The importance of NRs as targets of liver disease is exemplified by the number of NR ligands that are currently used in the clinics or in clinical trials with promising results. Understanding the regulation by NR during pathophysiological conditions, and identifying ligands for orphan NR, points to a potential therapeutic approach for patients with liver diseases. An overview of complex NR metabolic networks and their pharmacological implications in liver disease is presented here.
AB - Nuclear receptors (NR) are ligand-modulated transcription factors that play diverse roles in cell differentiation, development, proliferation, and metabolism and are associated with numerous liver pathologies such as cancer, steatosis, inflammation, fibrosis, cholestasis, and xenobiotic/drug-induced liver injury. The network of target proteins associated with NRs is extremely complex, comprising coregulators, small noncoding microRNAs, and long noncoding RNAs. The importance of NRs as targets of liver disease is exemplified by the number of NR ligands that are currently used in the clinics or in clinical trials with promising results. Understanding the regulation by NR during pathophysiological conditions, and identifying ligands for orphan NR, points to a potential therapeutic approach for patients with liver diseases. An overview of complex NR metabolic networks and their pharmacological implications in liver disease is presented here.
KW - Cholestatic liver disease
KW - Drug-induced liver injury
KW - Hepatocellular cancer
KW - Liver inflammation and fibrosis
KW - Nonalcoholic fatty liver
KW - Viral hepatitis infection
UR - http://www.scopus.com/inward/record.url?scp=84954154759&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84954154759&partnerID=8YFLogxK
U2 - 10.1146/annurev-pharmtox-010715-103209
DO - 10.1146/annurev-pharmtox-010715-103209
M3 - Article
C2 - 26738480
AN - SCOPUS:84954154759
SN - 0362-1642
VL - 56
SP - 605
EP - 626
JO - Annual Review of Pharmacology and Toxicology
JF - Annual Review of Pharmacology and Toxicology
ER -
